Editorial Staff

Hubwonk Ep. 7: Covid Testing: What went wrong, where we are & when we’ll get closer to normalcy

/0 Comments/in , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Join host Joe Selvaggi and Pioneer’s Bill Smith in a conversation with Hannah Mamuszka, expert in diagnostic medicine, on why the U.S. lacked adequate early testing, what current testing looks like in the Commonwealth, and where testing technology needs to be to support public gatherings in the future.

Interview Guest:

Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Posts

“Architecture is Frozen Music” Great Massachusetts Buildings – 25 Resources for K-12 Education

Understanding enduring public and private architecture is a key way to learn about art, ideas, and how they harmonize with our democracy. Yet, Massachusetts buildings are often never discussed in K-12 education. We’re offering a variety of links about outstanding houses and architecture across the Bay State for parents, teachers, and schoolchildren to enjoy, visit, and better appreciate, including:

COVID-19 Transparency – A Step Backwards

0 Comments
/
Massachusetts has unfortunately taken the backwards step of ending its longstanding daily reporting of something basic and important: the virus’s cumulative impact on various age groups.

Kelly Smith, Prenda CEO, on Microschooling & the Future of K-12 Learning

0 Comments
/
This week on “The Learning Curve,” Cara and Gerard are joined by Kelly Smith, founder and CEO of Prenda, a company that helps create flexible learning environments known as microschools. Often described as the “reinvention of the one-room school house,” microschools combine homeschooling, online education, smaller class sizes, mixed age-level groupings, flipped classrooms, and personalized learning.

Lockdowns – Lawless or Laudable? Grading Gov. Baker’s COVID-19 Emergency Orders 6 Months On

Join Joe Selvaggi and Pioneer Institute’s executive director Jim Stergios for a conversation with Boston Globe columnist Jeff Jacoby about the lawsuit against the Massachusetts Governor’s executive orders. They will explore what can be learned from the first six months of the COVID-19 pandemic, and what must be considered when devising a new way forward.

“City Upon a Hill” Massachusetts Monuments & Memorials: 25 Resources for K-12 Education

In Pioneer’s ongoing series of blogs here, here, here, and here on curricular resources for parents, families, and teachers during COVID-19, this one focuses on: Introducing K-12 schoolchildren to Massachusetts monuments & memorials.

U-Ark Prof. Jay Greene & EdChoice’s Jason Bedrick on Yeshivas vs. New York & Religious Liberty

0 Comments
/
This week on “The Learning Curve,” Cara and Gerard are joined by Jay Greene, the Distinguished Professor and Chair of the Department of Education Reform at the University of Arkansas, and Jason Bedrick, the Director of Policy for EdChoice. They discuss their timely new book, Religious Liberty and Education: A Case Study of Yeshivas vs. New York, about the recent battle between Orthodox Jewish private schools and New York's state government over the content of instruction.

Drug Rebates: How Pharmacy Benefit Managers Manipulate Price & Limit Choice

0 Comments
/
Join host Joe Selvaggi and his guest Dr. Bill Smith as they discuss the complex incentive structure between drug manufacturers, health plans, and pharmacy benefit managers. In this episode, they focus on how drug rebates work and how a system intended to optimize value may actually deliver higher costs and fewer choices. Joe and Bill also use this framework to speculate on the price of a COVID-19 vaccine, and who will likely pay for it.